drugset / Trial / NCT01792635
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindBasic science
Summary
This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
Timeline
- Start
- 2012-12
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-05175157 | Small molecule | 200 mg | Oral |